[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647644":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":25,"responsibleParty":75,"collaborators":10,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":10,"eligibilityCriteria":84,"healthyVolunteers":81,"sex":85,"minAge":86,"maxAge":10,"enrollmentInfo":87,"targetDuration":10,"studyType":90,"phases":10,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":109,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Stanford University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"BTKI Therapy",null,"Participants with chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma who are newly initiated on Bruton's tyrosine kinase inhibitor (BTKI) therapy. Participants are offered a smartwatch at enrollment for continuous monitoring and receive a clinically indicated ECG patch monitor 6 months after initiation of therapy if AF has not already been detected.",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-BTKI Therapy (Control)","Participants with the same hematologic malignancy diagnoses who are newly initiated on non-BTKI therapy (e.g., venetoclax-based regimens) instead of a BTKI. Participants are offered a smartwatch at enrollment for continuous monitoring and receive a clinically indicated ECG patch monitor 6 months after initiation of therapy if AF has not already been detected.",[16],{"name":17,"affiliation":5,"role":18},"Tina Baykaner, MD","PRINCIPAL_INVESTIGATOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Study Coordinator","CONTACT","707-628-2150","danieljg@stanford.edu",[26,46,62],{"facility":27,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"City of Hope","Duarte","California","91010","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-117.97729,34.13945,{"lat":37,"lon":36},[40,43],{"name":21,"role":22,"phone":41,"phoneExt":10,"email":42},"800-826-4673","jrhee@coh.org",{"name":44,"role":45,"phone":10,"phoneExt":10,"email":10},"June-Wha Rhee, MD","SUB_INVESTIGATOR",{"facility":47,"status":10,"city":48,"state":29,"zip":49,"country":31,"countryCode":32,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"UC San Diego Health","San Diego","92103",{"type":34,"coordinates":51},[52,53],-117.16472,32.71571,{"lat":53,"lon":52},[56,60],{"name":57,"role":22,"phone":58,"phoneExt":10,"email":59},"Ruby Swaim","858-246-2510","rswaim@health.ucsd.edu",{"name":61,"role":45,"phone":10,"phoneExt":10,"email":10},"Anna Narezkina, MD",{"facility":63,"status":10,"city":64,"state":29,"zip":65,"country":31,"countryCode":32,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Stanford Health Care","Stanford","94305",{"type":34,"coordinates":67},[68,69],-122.16608,37.42411,{"lat":69,"lon":68},[72,74],{"name":73,"role":22,"phone":23,"phoneExt":10,"email":24},"Daniel Gonzalez, MTM",{"name":17,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":76,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Tina Baykaner","Assistant Professor of Medicine (Cardiovascular Medicine)","100647644","atrial-fibrillation-among-patients-with-hematologic-malignancies-on-tyrosine-kinase-inhibitor-therapy-100647644",false,"NCT07711327","Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy","Inclusion Criteria:\n\n* Age greater than 18 years\n* Diagnosis of chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)\n* New initiation of Bruton's tyrosine kinase inhibitor (BTKI) therapy or non-BTKI therapy (eg, venetoclax based) for management of hematologic malignancy\n\nExclusion Criteria:\n\n* Prior exposure to BTKI therapy\n* History of persistent atrial fibrillation","ALL","18 Years",{"count":88,"type":89},500,"ESTIMATED","OBSERVATIONAL","This study looks at how often atrial fibrillation (AF), an irregular heart rhythm, occurs in people with certain blood cancers who are starting a type of cancer medicine called a Bruton's tyrosine kinase inhibitor (BTKI). Researchers will follow 400 people starting BTKI therapy and compare them to 100 people with similar blood cancers who are not taking a BTKI. Participants will wear a smartwatch and, later, a heart monitor patch to check for AF and other irregular heart rhythms over 12 months. The study will also look at whether AF affects cancer treatment, such as needing to pause, lower the dose, or stop the BTKI, and whether it leads to other health problems such as bleeding, stroke, or heart-related hospital visits.",[93,94,95,96,97],"Atrial Fibrillation (AF)","Chronic Lymphocytic Leukemia","Waldenstrom Macroglobulinemia","Mantle Cell Lymphoma","Marginal Zone Lymphoma",[99,100,101,102,103,104,105,106,107,108],"Bruton's Tyrosine Kinase Inhibitor","BTKI","Ibrutinib","Acalabrutinib","Zanubrutinib","Cardio-oncology","ECG patch monitor","Smartwatch monitoring","Arrhythmia","Hematologic malignancy","NOT_YET_RECRUITING","2026-07-14",{"date":112,"type":113},"2026-07-17","ACTUAL",{"date":115,"type":89},"2026-08",{"date":117,"type":89},"2031-08",{"name":77,"class":6},3]